Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Download in electronic PDF format for $75
Abstract: Morphine and sildenafil are commercially available at high concentrations which may lead to errors in measuring small volumes to provide low doses needed in infants. The purpose of this study was to assess the stability of morphine sulfate and sildenafil citrate in extemporaneously prepared suspensions for oral use. Morphine (0.2 mg/mL) was prepared from dilution of morphine elixir (2 mg/mL) with distilled water and stored in amber, plastic syringes at 25°C for 60 days. The mean concentration of morphine exceeded 95% of the initial concentration for the entire 60-day study period. No marked changes in pH or physical appearance were observed. Sildenafil (2.5 mg/mL) was prepared from Revatio tablets in two groups of suspensions: one group in 1% methylcellulose:simple syrup (1:7) and another in OraPlus:OraSweet (1:1). These were stored in plastic prescription bottles at 4°C and 25°C for a period of 91 days. The mean concentrations of sildenafil exceeded 95% of the original concentrations throughout the 91-day study period. No substantial changes were seen in the pH or physical appearance of the suspensions. These results indicate that the diluted morphine was stable for at least 60 days at room temperature. In addition, sildenafil was stable for 91 days in each of the two suspensions prepared from Revatio tablets and stored under refrigeration or at room temperature.
Related Keywords:
Milap C. Nahata, PharmD, MS, diluted morphine liquid, infants, children, sildenafil, pain, analgesia, analgesic, pulmonary hypertension, oral solution, oral suspension
Related Categories:
PAIN MANAGEMENT, PEDIATRICS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
|
May/Jun 2016
Pg. 247-249
|
Pediatric Compounding: Coloring Outside the Lines
Preckshot John
|
Jan/Feb 2001
Pg. 6-8
|
Women's Oral Health: Is There a Hormonal Link?
Preckshot John
|
Jan/Feb 2004
Pg. 10-14
|
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children
Pramann Lance A, Davidow Lawrence W, van Haandel Leon, Funk Ryan S
|
May/Jun 2016
Pg. 257-261
|
Application of Sildenafil for Pulmonary Hypertension in Canines and Foals
Davidson Gigi S
|
Nov/Dec 2006
Pg. 405-408
|
Treatment of Canine Pulmonary Hypertension: Is Tadalafil an Appropriate Alternative to Sildenafil?
Wung Deanna
|
Jan/Feb 2013
Pg. 24-27
|
Utilization of Compounded Medications in an Oral Medicine Practice
Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
|
Mar/Apr 2016
Pg. 155-158
|
Diverse Challenges in Pediatric Compounding: Treating Pulmonary Hypertension, Uncombable Hair Syndrome, and Acanthamoeba keratitis
Muller George, Young Thomas W, Reina Rachel, Caldwell Delmar R
|
Jan/Feb 2010
Pg. 40-45
|
Sildenafil Citrate 2.5-mg/mL Oral Liquid
Allen Loyd V Jr
|
Jul/Aug 2006
Pg. 306
|
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
|
Jan/Feb 2001
Pg. 9-12
|
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia
Robert Julien, Sorrieul Jérémy, Rossignol Elsa, Beaussart Hélène, Kieffer Hélène, Folliard Caroline, Dupoiron Denis, Devys Catherine
|
Jul/Aug 2017
Pg. 347-351
|
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
|
Mar/Apr 2017
Pg. 160-163
|
Oral Rehydration Salts (World Health Organization/United Nations Children's Fund)
Allen Loyd V Jr
|
Sep/Oct 2006
Pg. 390
|
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
|
Jan/Feb 2018
Pg. 66-75
|
Morphine Sulfate 0.2-mg/mL Solution Stored in Amber Oral Plastic Syringes
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 318
|
Oral Liquid Vehicles, Featured Excipient:
Allen Loyd V Jr
|
Jan/Feb 2001
Pg. 65-67
|
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro
|
Jul/Aug 2019
Pg. 324-331
|
Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension
Allen Loyd V Jr
|
May/Jun 2020
Pg. 230
|
Morphine Sulfate 10-mg/mL Oral Solution
Allen Loyd V Jr
|
May/Jun 2009
Pg. 243
|
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
|
Sep/Oct 2021
Pg. 431-439
|
Return to Top |